The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study “EMOTSIA”)

Medvedev, V.; Retiunsky, K. Yu.; Овчинников, А. А.; Barylnik, Yu. B.; Shmilovich, A A; Antokhin, E.; Usov, G. M.; Cheremin, R.; Poletsky, V. M.; Onegin, A. V.; Kireeva, I. P.; Фролова, В. И.; Филиппова, Н. В.; Antonova, A.; Deeva, M.; Onegina, D. A.

doi:10.17116/jnevro201611611126-34

Cited by 7 publications

(1 citation statement)

References 9 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Целью открытого психофармакотерапевтического исследования, выполненного на кафедре психиатрии, психотерапии и психосоматической патологии факультета непрерывного медицинского образования Медицинского института ФГАОУ ВО «Российский университет дружбы народов», являлась оценка эффективности и переносимости монотерапии мелатонинергическим тимолептиком агомелатином (вальдоксан) [12][13][14][15][16][17][18][19][20] при депрессии с симптомами РПП.…”

unclassified

Depressions with eating disorders: clinical manifestations and therapy

Medvedev

Фролова

Gushanskaya

et al. 2020

RJTAO

Self Cite

View full text Add to dashboard Cite

Depression is a common comorbid diagnosis in patients with eating disorders (EDs). The development of pathogenetic therapy for depression with EDs is far from being completed.The objective of the psychopharmacotherapeutic study was to evaluate the efficacy and tolerability of melatonergic monotherapy with the antidepressant agomelatine (25–50 mg/day at night) for depressions with two ED variants: hyperphagic (n=32) and hypo- and aphagic (n=31) EDs.Patients and methods. The investigation enrolled patients of both sexes, aged 18 to 65 years. The investigators performed clinical psychopathological and experimental psychological studies, as well as psychometric examination using the 21-item Hamilton Depression Rating Scale (HDRS-21), the Clinical Global Impression (CGI), the Supplemental Hospital Offset Payment Program (SHOPP), the Dutch Eating Behavior Questionnaire (DEBQ), and statistical data processing.Results and discussion. There was a significant pronounced antidepressant effect of 6-week agomelatine therapy for depressions occurring with different ED variants both in the pattern of the depressive symptom complex and in that of concurrent with and preceding the latter. At the same time, the efficacy of the drug did not depend on the clinical presentations of the leading hypothymic syndrome, the variants of EDs, and the duration of actual depression. However, by the end of the study period, a larger effect was achieved in the therapy for depressions with the hyperphagic variant of EDs, as well as in patients with EDs manifesting in the pattern of depressive symptom complex. Agomelatine has a favorable tolerance profile. BMI tends to become normal in patients with different variants of EDs during the therapy. The adverse events are transient and/or unclear; they do not require therapy discontinuation.Conclusion. Agomelatine is an effective and relatively safe drug that can be recommended to treat depressions concurrent with EDs in therapeutic dosages for at least 6 weeks.

show abstract

unclassified

Depressions with eating disorders: clinical manifestations and therapy

Medvedev

Фролова

Gushanskaya

et al. 2020

RJTAO

Self Cite

View full text Add to dashboard Cite

show abstract

Antidepressant therapy in patients with cardiovascular diseases

Medvedev

Korovyakova

Фролова

et al. 2019

Nevrologiâ, nejropsihiatriâ, psihosomatika

Self Cite

View full text Add to dashboard Cite

Депрессивные состояния являются наиболее частой формой психической патологии у пациентов общемедицинских амбулаторных и стационарных учреждений (5,9-24,9%), в том числе у страдающих сердечно-сосудистыми заболеваниями (ССЗ) [1-4]. В кардиологической практике частота депрессии достигает 15-38% [5-8]. По данным отечественного исследования психических расстройств в территориальной поликлинике и многопрофильной больнице, депрессивные состояния выявляются у 29% больных кардиологического отделения [9]. Среди факторов риска развития депрессии при ССЗ ведущие позиции занимают клинико-динамические харак-теристики соматического страдания или такие события, как острый инфаркт миокарда, аортокоронарное шунтирование, наличие других сопутствующих инвалидизирующих заболеваний, а также различные «кардиальные» типы личности-тип А, тип D [10-25]. С о ц и а л ь н о е и м е д и ц и н с к о е з н а ч е н и е д е п р е с с и и Депрессия входит в тройку заболеваний-лидеров с максимальными показателями дезадаптации, выраженными в количестве скорректированных по дезадаптации лет (Disability Adjusted Life Years, DALYs) [26-28]. По данным

show abstract

Impact of different classes of antidepressants on sleep and wakefulness regulation in depression

Usov

Kolomytsev

Anisimova

2022

RJTAO

Self Cite

View full text Add to dashboard Cite

Sleep disturbances are common in patients with mental disorders. Sleep disturbances, in particular insomnia, are widespread in depression. Depressed patients have a lot of sleep complaints that are often confirmed by polysomnography. Most antidepressants impair sleep, so drugs that help to restore sleep are of particular value in clinical practice. Agomelatine (valdoxan) rapidly improves sleep in depressed patients by making it easier to fall asleep, increasing total sleep time, duration of rapid eye movement (REM), and slow-wave sleep (SWS), and improving functioning during the day.

show abstract

The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study “EMOTSIA”)

Cited by 7 publications

References 9 publications

Depressions with eating disorders: clinical manifestations and therapy

Depressions with eating disorders: clinical manifestations and therapy

Antidepressant therapy in patients with cardiovascular diseases

Impact of different classes of antidepressants on sleep and wakefulness regulation in depression

Contact Info

Product

Resources

About